ArticlePloS one2026
Antioxidant, antibacterial, in vitro, and in silico α-glucosidase inhibition activities and chemical profiling of Usnea cornuta Korb.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The total phenolic content and flavonoid content of the Usnea cornuta extract were evaluated as 210.31 ± 2.87 mg GAE/g and 22.42 ± 0.78 mg QE/g, respectively. The crude extract exhibited strong antioxidant activity (IC50: 32.91 ± 1.27 µg/mL) and notable anti-diabetic effects via α-glucosidase inhibition, with IC50 values of 2.59 ± 2.23 µg/mL for the dichloromethane extract. LC-MS analysis identified eleven metabolites like D-mannitol (1), galbinic acid (2), conhypoprotocetraric acid (3), roccellaric acid (4), diffractatic acid (5), haemathamnolic acid isomer (6), conprotocetraric acid (7), constictic acid I (8), salazinic acid II (9), menegazziaic acid (10), and one unknown compound (11). Among these, menegazziaic acid exhibited the strongest binding affinity of -9.7 kcal/mol with the target (PDB ID 3A4A), favorable molecular dynamics, binding free energy (MM/GBSA, and pharmacokinetic profiles. Furthermore, the extract showed strong antimicrobial activity, with inhibition zones of 23 mm and 26 mm at 10 mg/mL against Staphylococcus aureus ATCC 29213 and ATCC 245, respectively. These findings highlight the therapeutic potential of Usnea cornuta, specifically for managing oxidative stress, microbial infections, and type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.